Clinical Trials Sponsored by Mundipharma CVA

Total 4849 results

Hutchison Medipharma Limited

Recruiting

Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

Relapsed/Refractory Follicular Lymphoma With EZH2

China
Hutchison Medipharma Limited

Recruiting

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin's Lymphoma

China
Hutchison Medipharma Limited

Recruiting

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Gastric Cancer | Esophagogastric Junction Disorder

China
Hutchison Medipharma Limited

Recruiting

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma

China
Hutchison Medipharma Limited

Recruiting

HMPL-453 in Advanced Malignant Mesothelioma

Advanced Malignant Mesothelioma

China
AstraZeneca
Hutchinson MediPharma (HMP)

Active, not recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Neoplasms by Site | Kidney Diseases | Carcinoma | Enzyme Inhibitors | Protein Kinase Inhibitors

United States, Italy, France, Korea, Republic of, Brazil, Russian Federation, Ukraine
Hutchison Medipharma Limited

Active, not recruiting

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer (FRESCO-2)

Metastatic Colorectal Cancer | Metastatic Colon Cancer

United States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
Hutchison Medipharma Limited

Completed

A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers

Healthy Subject

China
Hutchison Medipharma Limited

Completed

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Hutchison Medipharma Limited

Active, not recruiting

Phase III Study on HMPL-523 for Treatment of ITP

Primary Immune Thrombocytopenia (ITP)

China
Hutchison Medipharma Limited

Completed

Surufatinib Renal Impairment Study

Renal Impairment

United States
Hutchison Medipharma Limited

Completed

Surufatinib DDI With a PPI and a CYP3A Inducer

Healthy

United States
Hutchison Medipharma Limited

Completed

A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects

Healthy

United States
Hutchison Medipharma Limited

Unknown

HMPL-813 in Treating Patients With Glioblastoma

Glioblastoma

China
Hutchison Medipharma Limited

Completed

A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)

Healthy

China
Hutchison Medipharma Limited

Completed

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors

Solid Tumor

China
Hutchison Medipharma Limited

Completed

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

Food Effect of Fruquintinib in Health Subjects

China
Hutchison Medipharma Limited

Completed

A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Hutchison Medipharma Limited

Unknown

A Study of HMPL-453 in Patients With Advanced Solid Malignancies

Solid Tumor, Adult

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib

Healthy

China
Hutchison Medipharma Limited

Completed

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Thyroid Carcinoma

China
Hutchison Medipharma Limited

Completed

Phase II Study of HMPL-004 in Subjects With Crohn's Disease

Crohn's Disease
Hutchison Medipharma Limited

Completed

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer (FALUCA)

NSCLC

China
Hutchison Medipharma Limited

Terminated

A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies

Solid Tumor

Australia
Hutchison Medipharma Limited

Completed

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Taichung Veterans General Hospital
Taiwan Mundipharma Pharmaceuticals Ltd.

Unknown

Human Physiology and Self-Reported Pain Score

Cancer Pain

Taiwan
Mundipharma Manufacturing Pte Ltd.
Genome Institute of Singapore

Completed

The Effect of Skin Cleansers on the Skin Surface Microbiome

Skin Health

Singapore
Hutchison Medipharma Limited

Recruiting

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Advanced Renal Cell Carcinoma

China
Hutchison Medipharma Limited

Recruiting

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

China
Hutchison Medipharma Limited

Recruiting

Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT

Advanced Malignant Solid Tumors | TGCT

China
Hutchison Medipharma Limited

Recruiting

HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

Solid Tumor

China
Hutchison Medipharma Limited

Recruiting

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification (SACHI)

Non-small Cell Lung Cancer

China
Hutchison Medipharma Limited

Completed

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Tumors

United States, Italy
Hutchison Medipharma Limited

Active, not recruiting

HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA)

Warm Antibody Autoimmune Hemolytic Anemia

China
Hutchison Medipharma Limited

Completed

Surufatinib Hepatic Impairment Study

Hepatic Impairment

United States
Hutchison Medipharma Limited

Active, not recruiting

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Lung Sarcomatoid Carcinoma

China
Hutchison Medipharma Limited

Completed

A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

Healthy

United States
Hutchison Medipharma Limited

Unknown

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Biliary Tract Cancer

China
Hutchison Medipharma Limited

Terminated

Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Hutchison Medipharma Limited

Completed

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

NSCLC

China
Hutchison Medipharma Limited

Completed

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors (HMPL-504)

Tumors

China
Hutchison Medipharma Limited

Completed

A Food Effect Phase I Study of the Volitinib in Healthy Subjects (HMPL-504)

Food Effect | Health Subjects

China
Hutchison Medipharma Limited

Completed

Phase I Clinical Trial in Healthy Male Volunteers

Inflammatory Bowel Diseases
Hutchison Medipharma Limited

Terminated

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor (HMPL-309)

Cancer

China
Hutchison Medipharma Limited

Completed

To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers (CRC-C1721)

Relative Bioavailability

China
Hutchison Medipharma Limited

Completed

A Study of HMPL-689 in Healthy Volunteers

Healthy Volunteers

Australia
Mundipharma Pharmaceuticals S.L.
Alpha Bioresearch S.L.; Dynamic Solutions

Withdrawn

Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients

Persistent Asthma
PETHEMA Foundation
Janssen-Cilag Ltd.; Mundipharma Pharmaceuticals B.V.

Completed

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Spain
Research in Real-Life Ltd
Mundipharma Research Limited

Completed

Real-world Effectiveness of Combination Therapy in Asthma

Asthma

United Kingdom

Clinical Trials Sponsored by Mundipharma CVA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations